

<b>STUDY TITLE</b>	<b>SELECT STUDY- Semaglutide effects on cardiovascular outcomes in people with overweight or obesity</b>
<b>STUDY POPULATION</b>	<b>Patients have established CV disease</b>
<b>PRINCIPAL INVESTIGATOR</b>	Dato' Sri Dr. Haji Azhari Rosman
<b>STUDY COORDINATOR</b>	Norasiah Basri Contact number : 03 – 2617 8200 Ext: 3122
<b>START DATE</b>	01 Apr 2019
<b>END DATE</b>	16 Nov 2023
<b>INCLUSION</b>	<ul style="list-style-type: none"> <li>• Age <math>\geq</math> 45 years</li> <li>• Body mass index (BMI) <math>\geq</math> 27kg/m<sup>2</sup></li> <li>• Have established CV disease as evidenced by at least one of the following: <ul style="list-style-type: none"> <li>• Prior MI &gt; 60 days prior to the day of screening</li> <li>• Prior stroke &gt; 60 days prior to the day of screening</li> <li>• Symptomatic PAD, as evidenced by intermittent claudication with ABI &lt; 0.85 (at rest), or peripheral arterial revascularization procedure, OR amputation due to atherosclerotic disease</li> </ul> </li> </ul>
<b>EXCLUSION</b>	<ul style="list-style-type: none"> <li>• Cardiac events (MI, Stroke, hospitalization for UA pectoris or TIA ) within 60 days prior to the day of screening</li> <li>• Planned coronary, carotid or peripheral artery revascularization known on the day of screening</li> <li>• Presently classified as being NYHA Class IV heart failure</li> <li>• HbA1c <math>\geq</math> 48 mmol/mol (6.5%) as measured by the central lab at screening</li> <li>• History of type 1 or type 2 DM ( history of gestational diabetes is allowed)</li> <li>• Treatment with glucose –lowering agents within 90 days before screening</li> <li>• Treatment with any GLP-1 RA within 90 days before screening</li> </ul>